Thursday, February 18, 2010

BCBSNC to increase restricted-access drugs

Effective April 1, 2010, BCBSNC will expand its restricted-access drug list for the following classes:

Triptans: commonly used in migraine therapy; users of non-preferred triptans (Amerge, Axert, Frova, Sumavel DosePro, Treximet, Zomig, and Zomig ZMT) will be required to try sumatriptan (generic Imitrex), Relpax, Maxalt or Maxalt MLT before the non-preferred drug will be covered.

Selective Serotonin Reuptake Inhibitors (SSRIs): commonly used to treat depression, obsessive-compulsive disorder and/or anxiety disorders; new users of non-preferred SSRIs (Lexapro, Luvox CR and Pexeva) will be required to try the generics citalopram, fluoxetine, fluvoxamine, paroxetine, or sertraline before the non-preferred drug will be covered.

Hypnotics: commonly used to treat insomnia; users of non-preferred hypnotics (Ambien CR, Edluar, Lunesta, Rozerem, and Zolpimist) will be required to try the generics zaleplon or zolpidem before the non-preferred drug will be covered.

These restrictions are meant to encourage the use of generics and preferred brand-name drugs in an effort to provide quality, cost-effective health care. BCBSNC will send notification letters to affected members next month. Click to access the Sample Client Letter and Drug Update FAQ from BCBSNC.

No comments:

Post a Comment